GILEAD SCIENCES, INC.·4

Mar 12, 4:24 PM ET

O'Day Daniel Patrick 4

4 · GILEAD SCIENCES, INC. · Filed Mar 12, 2026

Research Summary

AI-generated summary of this filing

Updated

Gilead (GILD) CEO Daniel O'Day Exercises Options, Sells Shares

What Happened

  • Daniel Patrick O'Day (Chairman & CEO, Director) executed option-related transactions on 2026-03-10: he exercised options covering 20,026 shares and was granted restricted stock units (RSUs) of 32,815 and 122,755 shares (total RSUs granted = 155,570). To satisfy tax withholding, 9,767 shares were surrendered/disposed at $148.56 per share for proceeds (value) of $1,450,986. The filings show derivative activity associated with the option exercise and RSU grants.

Key Details

  • Transaction date: March 10, 2026; Form 4 filed March 12, 2026 (appears timely).
  • Option exercise: 20,026 shares (code M — exercise/conversion of derivative).
  • RSU grants: 32,815 shares (code A) and 122,755 shares at $0.00 (code A) — total 155,570 RSUs granted.
  • Tax/withholding disposition: 9,767 shares disposed (code F) at $148.56 = $1,450,986 (used to cover taxes/exercise price).
  • Shares owned after the transaction: not specified in the Form 4 provided.
  • Footnotes: F1 — each RSU converts to one share on vesting; F2 — RSUs vest over four years (25% after one year, then 6.25% quarterly); F3 — stock options vest over four years with similar schedule.

Context

  • The pattern (exercise of options coupled with a share disposition labeled F) is consistent with a cashless exercise or withholding of shares to satisfy tax obligations rather than an open-market sale for cash. RSU grants and option exercises are common executive compensation events and do not by themselves indicate a change in insider sentiment.

Insider Transaction Report

Form 4
Period: 2026-03-10
O'Day Daniel Patrick
DirectorChairman & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-10+20,026662,334 total
  • Tax Payment

    Common Stock

    2026-03-10$148.56/sh9,767$1,450,986652,567 total
  • Exercise/Conversion

    Restricted Stock Unit

    [F1][F2]
    2026-03-1020,02668,044 total
    Common Stock (20,026 underlying)
  • Award

    Restricted Stock Unit

    [F1][F2]
    2026-03-10+32,815100,859 total
    Common Stock (32,815 underlying)
  • Award

    Non-qualified Stock Option (Right to Buy)

    [F3]
    2026-03-10+122,755122,755 total
    Exercise: $148.56Exp: 2036-03-10Common Stock (122,755 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
  • [F2]The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
  • [F3]The stock options have a four-year vesting schedule. 25% of the options vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Signature
/s/ Amy Kim by Power of Attorney for Daniel O'Day|2026-03-12

Documents

1 file
  • 4
    wk-form4_1773347089.xmlPrimary

    FORM 4